预约演示

更新于：2025-01-23

TP53RK

更新于：2025-01-23

基本信息

别名

Atypical serine/threonine protein kinase TP53RK、BUD32、C20orf64

+ [11]

简介

Component of the EKC/KEOPS complex that is required for the formation of a threonylcarbamoyl group on adenosine at position 37 (t(6)A37) in tRNAs that read codons beginning with adenine (PubMed:22912744, PubMed:27903914). The complex is probably involved in the transfer of the threonylcarbamoyl moiety of threonylcarbamoyl-AMP (TC-AMP) to the N6 group of A37 (PubMed:22912744, PubMed:27903914). TP53RK has ATPase activity in the context of the EKC/KEOPS complex and likely plays a supporting role to the catalytic subunit OSGEP (By similarity). Atypical protein kinase that phosphorylates 'Ser-15' of p53/TP53 protein and may therefore participate in its activation (PubMed:11546806).

关联

项与 TP53RK 相关的药物

Alpha ketoglutarate

靶点

Reactive oxygen species x TP53RK

作用机制

活性氧刺激剂 [+1]

在研机构

山东大学

原研机构

Institute of Nuclear Medicine & Allied Sciences

在研适应症

弥漫性大B细胞淋巴瘤

非在研适应症

中毒

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

项与 TP53RK 相关的临床试验

CTRI/2013/02/003355

/ Recruiting临床2期

An open labeled, comparative, step-up phase-2 clinical study to assess bioavailability and efficacy of sodium alpha-ketoglutarate infusion injection in patients with cyanide overload

开始日期2012-08-31

申办/合作机构

Defence Research & Development Establishment

CTRI/2013/01/003331

/ Recruiting临床2期

A phase-II open labeled, comparative, field study to assess efficacy of oral sodium alpha-ketoglutarate in treating cyanide poisoning

开始日期2012-08-31

申办/合作机构

Defence Research & Development Establishment

CTRI/2013/02/003356

/ Recruiting临床2期

An open labeled, comparative, step-up phase-II clinical study to assess deposition and efficacy of sodium alpha-ketoglutarate nebulization fluid (submicron-sized) in management of hydrogen cyanide, methyl isocyanate (MIC) toxicity and ammonia gas exposure

开始日期2012-08-31

申办/合作机构

Defence Research & Development Establishment

100 项与 TP53RK 相关的临床结果

登录后查看更多信息

100 项与 TP53RK 相关的转化医学

登录后查看更多信息

0 项与 TP53RK 相关的专利（医药）

登录后查看更多信息

项与 TP53RK 相关的文献（医药）

2024-05-08·Nucleic Acids Research

Molecular basis of A. thaliana KEOPS complex in biosynthesizing tRNA t6A

Article

作者: Zhu, Li ; Duan, Lei ; Zhang, Wenhua ; Jin, Mengqi ; Su, Chenchen ; Zheng, Xinxing ; Sun, Yongtao

AbstractIn archaea and eukaryotes, the evolutionarily conserved KEOPS is composed of four core subunits―Kae1, Bud32, Cgi121 and Pcc1, and a fifth Gon7/Pcc2 that is found in fungi and metazoa. KEOPS cooperates with Sua5/YRDC to catalyze the biosynthesis of tRNA N6-threonylcarbamoyladenosine (t6A), an essential modification needed for fitness of cellular organisms. Biochemical and structural characterizations of KEOPSs from archaea, yeast and humans have determined a t6A-catalytic role for Kae1 and auxiliary roles for other subunits. However, the precise molecular workings of KEOPSs still remain poorly understood. Here, we investigated the biochemical functions of A. thaliana KEOPS and determined a cryo-EM structure of A. thaliana KEOPS dimer. We show that A. thaliana KEOPS is composed of KAE1, BUD32, CGI121 and PCC1, which adopts a conserved overall arrangement. PCC1 dimerization leads to a KEOPS dimer that is needed for an active t6A-catalytic KEOPS–tRNA assembly. BUD32 participates in direct binding of tRNA to KEOPS and modulates the t6A-catalytic activity of KEOPS via its C-terminal tail and ATP to ADP hydrolysis. CGI121 promotes the binding of tRNA to KEOPS and potentiates the t6A-catalytic activity of KEOPS. These data and findings provide insights into mechanistic understanding of KEOPS machineries.

2024-01-30·mSphere

Sua5 catalyzing universal t ⁶ A tRNA modification is responsible for multifaceted functions of the KEOPS complex in Cryptococcus neoformans

Article

作者: Hyeon, Hana ; Bahn, Yong-Sun ; Choi, Yeseul ; Lee, Kangseok

ABSTRACT The N 6 -threonylcarbamoyl adenosine (t 6 A) tRNA modification is critical for ensuring translation fidelity across three domains of life. Our prior work highlighted the KEOPS complex, organized in a Pcc1-Kae1-Bud32-Cgi121 linear arrangement, not only serves an evolutionarily conserved role in t 6 A tRNA modification but also exerts diverse functional impacts on pathobiological characteristics in Cryptococcus neoformans , a leading cause of fungal meningitis worldwide. However, the extent to which the pleiotropic functions of the KEOPS complex are specifically tied to tRNA modification remains uncertain. To address this, we undertook a functional characterization of Sua5, responsible for generating the precursor threonylcarbamoyl-adenylate (TC-AMP) for t 6 A tRNA modification, using a reverse genetics approach. Comparative phenotypic analyses with KEOPS mutants revealed that Sua5 plays a vital role in multiple cellular processes, such as t 6 A tRNA modification, growth, sexual development, stress response, and virulence factor production, thus reflecting the multifaceted functions of the KEOPS complex. In support of this, sua5 Δ bud32 Δ double mutants showed phenotypes comparable to those of the corresponding single mutants. Intriguingly, a SUA5 allele lacking a mitochondria targeting sequence ( SUA5 MTSΔ ) was sufficient to restore the wild-type phenotypes in the sua5 Δ mutant, suggesting that Sua5’s primary functional locus may be cytosolic, akin to the KEOPS complex. Further supporting this, the deletion of Qri7, a mitochondrial paralog of Kae1, had no discernible phenotypic impact on C. neoformans . We concluded that cytosolic t 6 A tRNA modifications, orchestrated by Sua5 and the KEOPS complex, are central to the regulation of diverse pathobiological functions in C. neoformans . IMPORTANCE Understanding cellular functions at the molecular level is crucial for advancing disease treatments. Our research reveals a critical connection between the KEOPS complex and Sua5 in Cryptococcus neoformans , a significant cause of fungal meningitis. While the KEOPS complex is known for its versatile roles in cellular processes, Sua5 is specialized in t 6 A tRNA modification. Our key finding is that the diverse roles of the KEOPS complex, ranging from cell growth and stress response to virulence, are fundamentally linked to its function in t 6 A tRNA modification. This conclusion is supported by the remarkable similarities between the impacts of Sua5 and KEOPS on these processes, despite their roles in different steps of the t 6 A modification pathway. This newfound understanding deepens our insight into fungal biology and opens new avenues for developing potential therapies against dangerous fungal diseases.

2023-11-09·Cancer Research Communications

Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription

Article

作者: Izumi, Raquel ; Frigault, Melanie M ; Hamdy, Ahmed ; Huang, Xin ; Johnson, Amy J ; Wong, Harvey ; Stelte-Ludwig, Beatrix ; Birkett, Joseph ; Mithal, Arushi ; Mandava, Vinay

AbstractDouble-hit diffuse large B-cell lymphoma (DH-DLBCL) is an aggressive, and often refractory, type of B-cell non–Hodgkin lymphoma (NHL) characterized by rearrangements in MYC and BCL2. Cyclin-dependent kinase 9 (CDK9) regulates transcriptional elongation and activation of transcription factors, including MYC, making it a potential targeted approach for the treatment of MYC+ lymphomas. Enitociclib is a well-tolerated and clinically active CDK9 inhibitor leading to complete metabolic remissions in 2 of 7 patients with DH-DLBCL treated with once weekly 30 mg intravenous administration. Herein, we investigate the pharmacodynamic effect of CDK9 inhibition in preclinical models and in blood samples from patients [DH-DLBCL (n = 10) and MYC+ NHL (n = 5)] treated with 30 mg i.v. once weekly enitociclib. Enitociclib shows significant regulation of RNA polymerase II Ser2 phosphorylation in a MYC-amplified SU-DHL-4 cell line and depletion of MYC and antiapoptosis protein MCL1 in SU-DHL-4 and MYC-overexpressing SU-DHL-10 cell lines in vitro. Tumor growth inhibition reaching 0.5% of control treated SU-DHL-10 xenografts is achieved in vivo and MYC and MCL1 depletion as well as evidence of apoptosis activation after enitociclib treatment is demonstrated. An unbiased analysis of the genes affected by CDK9 inhibition in both cell lines demonstrates that RNA polymerase II and transcription pathways are primarily affected and novel enitociclib targets such as PHF23 and TP53RK are discovered. These findings are recapitulated in blood samples from enitociclib-treated patients; while MYC downregulation is most robust with enitociclib treatment, other CDK9-regulated targets may be MYC independent delivering a transcriptional downregulation via RNA polymerase II.Significance:MYC+ lymphomas are refractory to standard of care and novel treatments that downregulate MYC are needed. The utility of enitociclib, a selective CDK9 inhibitor in this patient population, is demonstrated in preclinical models and patients. Enitociclib inhibits RNA polymerase II function conferring a transcriptional shift and depletion of MYC and MCL1. Enitociclib intermittent dosing downregulates transcription factors including MYC, providing a therapeutic window for durable responses in patients with MYC+ lymphoma.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

来和芽仔聊天吧

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。